Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scandion Oncology – Interim Report Q2 2022

Scandion Oncology (Scandion) today announces its interim report for Q2 2022. The following is taken from the report. Bo Rode Hansen, President and CEO, comments “The second quarter of 2022 saw us raise capital to fund our operations into 2024 and maintain momentum in our clinical trials as we continue to execute on our strategy to ensure long term value creation” Key Figures & Highlights TDKK Q1 2022 Q1-Q2 2022 Q1 2021 Q1-Q2 2022 FY 2021 Operating -24,840 -41,152 -15,493 -25,397 -55,367loss Net finance -37 -

Interim Report January - June 2022

April 1st – Jun 30th 2022 · Net sales amounted to EUR 6 763 thousand (6 246), an 8.3 percent increase · EBITDA of EUR 301 thousand (383) and EBITDA margin of 4.4 % (6.1) · EBIT of EUR 194 thousand (286) and EBIT margin of 2.9% (4.6) · Net earnings after tax of positive EUR 106 thousand (19)   Jan 1st – Jun 30th 2022 · Net sales amounted to EUR 12 899 thousand (11 937), an 8.1 percent increase · EBITDA of EUR 365 thousand (432) and EBITDA margin of 2.8 percent (3.6) · EBIT of EUR 157 thousand (238) and EBIT margin of 1.2 percent (2) · Net earnings after tax

Pharmacolog: Interim report January - June 2022

Press release: Uppsala, August 25, 2022. Pharmacolog i Uppsala AB’s (publ) interim report for the period January – June is now available on the company’s webbsite http://www.pharmacolog.com (Swedish only)Andra kvartalet 1 april – 30 juni 2022 · Koncernens nettoomsättning för det andra kvartalet uppgick till 3 221 (939) KSEK. · Rörelseresultatet för koncernen för perioden uppgick till -4 783 (-4 786) KSEK. · Nettoresultat per aktie före och efter utspädning var för perioden -0,31 (-0,38) SEK. Halvåret 1 januari – 30 juni 2022 · Koncernens nettoomsättning för halvåret

Arctic Paper appoints business developer for the energy area

Arctic Paper has recruited Daniel Bergkvist to a new position as Group Business developer with responsibility for the group's activities in the energy area. Daniel Bergkvist is a Swedish citizen with experience in, among other things, energy issues and international business. He will report to the group CEO.Investments in renewable and fossil-free energy with the aim of the group becoming carbon dioxide neutral by 2030 is an important part of Arctic Paper's strategy. The group invests in green energy solutions such as hydropower in Munkedal, biomass in Grycksbo and solar cells in Kostrzyn.

Saga Pure ASA: Ex. dividend NOK 0.10 on 6 September 2022

Reference is made to the announcement by Saga Pure ASA concerning, inter alia, the Board of Directors' resolution to distribute a cash dividend of NOK 0.10 per share. Key information relating to the cash dividend is set out below:Issuer: Saga Pure ASA Dividend per share: NOK 0.10 Announced currency: NOK Last day inclusive: 5 September 2022 Ex. date: 6 September 2022 Record Date: 7 September 2022 Payment Date: On or about 14 September 2022 Date of resolution: 24 August 2022 This information is published in accordance with the requirements of the Continuing Obligations.

Brighter’s Board of Directors secures financing for further commercialization through a rights issue of units of approximately SEK 52.4 million and procures loan financing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. The Board of Directors of Brighter AB (publ) (“Brighter” or the “Company”) has today, with authorization from the general meeting in the Company on June 8, 2022,

Ultomiris approved in Japan for gMG

25 August 2022 07:10 BST Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis First and only long-acting C5 complement inhibitor offers early onset and sustained efficacy, and has the potential to reduce treatment burden with dosing every 8 weeks  Ultomiris (ravulizumab) has been approved in Japan for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy (IVIg) or

Himalaya Shipping Ltd. (HSHIP) – Installation of Exhaust Gas Cleaning System

Hamilton, Bermuda, August 25, 2022  Himalaya Shipping Ltd. (the “Company”) is pleased to announce that it has decided to install scrubbers (EGCS) on the entire fleet of twelve vessels presently under construction at New Times Shipyard (“NTS”) in China. The installation will be done within the previously agreed delivery schedule from the shipyard at attractive prices and payment terms. After installation of scrubbers, the ships will have the ability to be fuelled with LNG, LSFO or HSFO. This offers significant increased flexibility for our customers and will be valuable in the ongoing

Tagrisso approved in Japan for early lung cancer

25 August 2022 07:05 BST Tagrisso approved in Japan for the adjuvant treatment ofpatients with early-stage EGFR-mutated lung cancer Tagrisso is the only EGFR-targeted medicine approved in Japan for thetreatment of early-stage lung cancer after surgery Approval based on results from the ADAURA Phase III trial AstraZeneca's Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery. This approval by the Japanese Ministry of Health, Labour and

Idogen publishes interim report for 1 January – 30 June 2022

Idogen AB's interim report for January to June 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/   Second quarter (April-June 2022) • Other operating income amounted to KSEK 159 (1,731) • Operating loss was KSEK -11,157 (-9 541) • Loss for the quarter totalled KSEK -11,196 (-9,604) • Cash flow from operating activities was KSEK -10,172 (-6,135) • Loss per share before dilution was SEK -0.15 (-0.53). Loss per share after dilution was SEK -0.15 (-0.53)   Period (January-June 2022) • Other operating income amounted to

Saga Pure: Second quarter 2022 financial results

(Oslo, 25 August 2022) Saga Pure ASA (Saga Pure, OSE: SAGA) reported a net profit for the second quarter 2022 of NOK 138 million (Q2 2021: NOK 3.5 million), corresponding to a year-to-date return on equity of 17.8 percent. The Board of Directors has decided to distribute a dividend of NOK 0.1 per share.“Having worked very actively with our biggest investment, Bergen Carbon Solutions, over the last year and a half, we stepped down from the board in May. This resulted in a change of the classification of the investment from an associated company to a non-current financial asset. With profit

Alzinova AB interim report January – June 2022

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - June 2022Three months, April – June 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -3,299,600 SEK (-2,179,986 SEK). · Earnings per share amounted to -0.10 SEK (-0.14 SEK). Six months, January – June 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -5,581,756 SEK (-3,641,239 SEK). · Earnings per share amounted to -0.17 SEK (-0.23 SEK). · Equity ratio amounted

Efterklang is awarded two Red Dot Design Awards 2022

Efterklang, part of AFRY, is a leader in sound design and consists of engineers, designers and technical specialists in sound. Efterklang has been awarded two Red Dot Design Awards in the discipline Brand & Communication Design 2022 for The Yale Audio Experience for ASSA ABLOY and for the sound environment at Vasakronan’s co-working concept and headquarters Arena Sergel.Efterklang has extensive experience in designing and adding sound to places, brands and products to amplify emotional reactions, complement visual impressions and enhance user experiences. Because of this, Efterklang was

Cyclyx partners with Virgin Red to bring incentives and rewards to plastic recycling

PORTSMOUTH, New Hampshire, USA, August 25, 2022 – Cyclyx International , a consortium-based post-use plastic innovation company with a mission to increase the recyclability of plastic from 10% to 90%, has announced a partnership with Virgin Red , the rewards club from the Virgin Group. The partnership will drive behavioural changes in plastic recycling by offering Virgin Points to incentivize participation in Cyclyx’s 10 to 90® 

Every second German considers buying an electric or hybrid car

Representative survey: 48 percent are willing to pay a higher price for sustainable battery production - 57 percent support more mining in Europe for critical minerals Electromobility is the buzz word of our time. But where do the raw materials that are urgently needed for the electric revolution come from? Lithium, cobalt, nickel, and copper - without these minerals, the manufacture of batteries and thus the production of electric cars is not possible. The mining company Eurobattery Minerals  (Nordic Growth Market: BAT  and

Lynparza approved in Japan for early breast cancer

25 August 2022 07:00 BST Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer First and only approved medicine targetingBRCA mutations in early breast cancer AstraZeneca and MSD's Lynparza (olaparib) has been approved in Japan for the adjuvant treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence. This approval by the Japanese Ministry of Health, Labour, and Welfare was based on results from the OlympiA Phase III trial 

Asetek and Pagani Automobili Announce Pagani Huayra R Sim Racing Pedals by Asetek SimSports™

As-Near-As-It-Gets to the Pagani Huayra R Real Driving Experience on Sim RigAalborg, Denmark – August 25, 2022 –– Asetek, sim racing gear innovator, along with world-renowned hypercar Atelier Pagani Automobili announced the Asetek SimSports™’ Pagani Huayra R Sim Racing Pedals. Now the most passionate sim racers and car enthusiasts can virtually experience the rush of driving a real Pagani, the world’s most exclusive hypercar brand, with the Pagani-branded sim racing pedal set from Asetek SimSports™. “We are thrilled with the extreme quality, design and premium performance of these Pagani-

Interim report, January - June 2022

In Q2 2022 net sales increased by 14.4% compared to Q2 2021. Consolidated net sales ended at 61,066 (SEK 000s). EBITDA totaled to -30,988 (SEK 000s). Operating profit, EBIT, was -52,286 (SEK 000s). Profit after tax was -63,669 (SEK 000s). Earnings per share was SEK -0.94. For 1H 2022 net sales increased by 24.0% compared to 1H 2021. Consolidated net sales ended at 126,383 (SEK 000s). EBITDA totaled to -47,253 (SEK 000s). Operating profit, EBIT, was -88,410 (SEK 000s). Profit after tax was -92,840 (SEK 000s). Earnings per share was SEK -1.37.CEO's comments Moderate growth in first half

Aiforia Technologies Plc Half-year report 1 January-30 June 2022

Aiforia Technologies Plc Half-year report 1 January-30 June 2022 (unaudited) | Aiforia Technologies Plc, Company Release, 25 August 2022, 9:00 a.m. EESTThis release is a summary of the Aiforia Technologies Plc Half-year report for 1 January-30 June 2022. You can find the whole Half-year report attached as a PDF.   The figures in brackets refer to the corresponding period of the previous year, unless otherwise indicated.   Key figures for January-June 2022 ●       Aiforia’s net sales increased by 72% from the comparison period and amounted to EUR 733 (426) thousand ●

Lytix Biopharma: Second quarter and first half of 2022 results

Lytix Biopharma, a Norwegian immune-oncology company, today releases its second quarter and first half 2022 results – New encouraging clinical data.“The first six months of 2022 have been fueled by clinical development and clinical data presentations across international conferences alongside seeing our partner Verrica Pharmaceuticals advance its Phase II study evaluating LTX-315 for basal cell carcinoma. For Lytix, the most significant clinical trial development was the completion of the Phase II study evaluating LTX-315 in combination with adoptive therapy (ACT) in soft tissue sarcoma

Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022

Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the year-end report for the fiscal year 2021/2022. Below is a summary of the report. The full report is available on the Eurocine Vaccines website and as an attachment. 2022-04-01 - 2022-06-30 (fourth quarter) · Results after tax for the quarter amounted to -5,2 MSEK (-6,1 MSEK) · Revenues for the quarter amounted to 43 KSEK (2 KSEK) · Earnings per share for the quarter amounted to -0,299 SEK (-0,768 SEK) 2021-07-01 - 2022-03-31 (fiscal year, twelve months) · Results after

Arctic Bioscience – Revenue growth and HRO350 Phase IIb clinical trial on track

Highlights H1 2022 results:· HRO350 development on track with further projects in pipeline · First patient expected to be enrolled in Q4 2022 · Total revenue increased 20 % y/y to NOK 14,4 million in H1 2022, from NOK 12 million in H1 2021 · EBITDA of NOK -14,4 million in H1 2022 (NOK -19,9 million), with a gross margin of 27,6 % (26,0 %) · Solid financial position with NOK 177,8 million in cash by 30 June · Positive revenue prospects for H2 2022, including increased order intake from the Chinese market · Strong Management team in place, including new CEO, new CFO and new

Financial Report 2nd quarter for DOF ASA

The Group's revenue for 2nd quarter (management reporting) totals NOK 2,510 million (NOK 2,003 million) and EBITDA totals NOK 848 million (NOK 680 million). The operating profit (EBIT) is NOK 501 million (NOK 148 million), of which depreciation totals NOK 346 million (NOK 313 million). No impairment in 2[nd] quarter (NOK 218 million). Net financial cost amounts to NOK 1,746 million (NOK 531 million) including unrealised currency loss of NOK -1,502 million (gain NOK 815 million). The result is a loss of NOK -1,313 million (profit NOK 580 million). Operations: · Average utilisation of

Faron Reports 2022 Half-Year Financial Results

Faron Pharmaceuticals Oy (“Faron” or “Company”)   Faron Reports Half-Year Financial Results, January 1 – June 30, 2022   August 25, 2022 at 2:00 am EDT / 7:00 am BST / 9:00 am EEST   Summary of January – June 2022 · New data reinforces bexmarilimab’s potential to bring the promise of immunotherapy to cancer patients who are currently not benefiting from approved checkpoint inhibitors · Compelling 12-month survival data reported from Phase I/II MATINS study with 100% survival among checkpoint refractory melanoma and cholangiocarcinoma patients who benefited from

There are no items matching the current filter
There are no more items matching the current filter
Back to top